Get SCDM CCDM Exam Practice Questions - Real and Updated

Answer : D

The most effective information for addressing a backlog of unresolved queries at investigative sites is a list of late queries by site combined with a summary table.

According to the GCDMP (Chapter: Communication and Issue Escalation), timely and structured feedback to sites is critical for efficient query resolution. A detailed list of late or overdue queries, accompanied by summary statistics (e.g., counts, durations, status), enables data managers and monitors to prioritize follow-up actions, target problem areas, and provide focused support or retraining to underperforming sites.

While query count summaries (option B) are helpful for overview metrics, they lack the specific information (query ID, date, field, status) required for targeted follow-up. Graphs of enrollment or clean cases (options A and C) are unrelated to discrepancy resolution performance.

Thus, the combination of detailed lists and summarized performance metrics offers both granularity and a high-level overview --- the optimal tool for query management communication.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Communication and Issue Escalation, Section 5.1 -- Site Query Management Reports

ICH E6 (R2) GCP, Section 5.18.4 -- Communication Between Monitors and Sites

FDA Guidance for Industry: Oversight of Clinical Investigations -- Risk-Based Monitoring, Section on Query Metrics and Site Performance Review

Answer : B

When adverse events (AEs) are discovered after a database lock, the appropriate first step is to evaluate the impact of the missing data on the integrity, safety analysis, and regulatory validity of the study results.

According to GCDMP (Chapter: Data Quality Assurance and Control), any post-lock data discovery requires a root cause assessment and impact analysis before deciding whether to unlock the database. The key question is whether the missing AEs:

Affect primary safety endpoints,

Introduce bias in safety reporting, or

Alter efficacy conclusions.

Based on the assessment, the Data Management and Biostatistics teams determine if unlocking and correction are justified. Simply entering data immediately (A) or repeating checks (D) without analysis may violate data control procedures.

Hence, option B is correct --- the first step is to assess the impact on data validity and analysis.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 5.5 -- Post-Lock Findings and Impact Assessment

ICH E6(R2) GCP, Section 5.1.1 -- Quality Management and Risk Assessment

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 -- Post-Lock Data Management

Answer : A

The best practice when implementing a protocol amendment that affects CRF content or data collection timing is to update the eCRF completion guidelines and notify sites before implementing the change.

According to the GCDMP (Chapter: CRF Design and Data Collection), the eCRF Completion Guidelines (eCRF CG) are an essential study tool that instructs site personnel on accurate and consistent data entry. When new data elements or collection time points are added, the guidelines must be revised, version-controlled, and communicated to all users prior to implementation to ensure sites collect and enter data correctly.

Simply relying on the revised CRF (option C) or updating the document without notification (option B) violates communication and training standards. Likewise, notifying sites without updating the documentation (option D) leaves insufficient reference material for data entry compliance.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 5.5 -- Managing CRF Revisions and Site Communication

ICH E6 (R2) GCP, Section 5.18.4 -- Communication of Protocol Amendments and Documentation Updates

FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 4.3 -- Site Communication and Documentation Management

Answer : C

Testing query rules with test data inputs to confirm expected outputs without examining the underlying program logic is an example of black box testing.

According to the GCDMP (Chapter: Data Validation and System Testing), black box testing is a functional testing approach used to verify that the system performs correctly from the end-user's perspective. In this method, testers input various conditions and observe outputs to ensure the system behaves as intended --- for instance, that edit checks trigger correctly when data fall outside predefined limits.

In contrast, white box testing involves examining internal logic, code, and algorithm structures. Because data managers typically validate edit checks through data-driven test cases rather than code inspection, black box testing is the appropriate and industry-standard method. This ensures compliance with validation documentation standards as outlined in FDA 21 CFR Part 11, Section 11.10(a) and ICH E6 (R2) system validation expectations.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Validation and Testing, Section 4.1 -- Testing Approaches (Black Box and White Box)

FDA 21 CFR Part 11 -- System Validation Requirements

ICH E6 (R2) GCP, Section 5.5.3 -- Computerized Systems Validation

Answer : D

The most essential Standard Operating Procedure (SOP) for management of an Electronic Data Capture (EDC) system is Change Control.

Per GCDMP (Chapter: Computerized Systems and Compliance) and FDA 21 CFR Part 11, any changes made to an EDC system---whether to software configuration, study database design, or system functionality---must follow a documented, validated, and auditable change control process. This ensures that:

Modifications are properly authorized, tested, and approved before implementation.

System validation remains intact.

Data integrity, traceability, and regulatory compliance are maintained.

While vendor management (A) and coding maintenance (C) have supporting SOPs, change control (D) is mandatory for any system handling regulated clinical data. Measurement of data quality (B) is important but not specifically tied to system management procedures.

Thus, option D (Change control) is the correct answer.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 5.3 -- Change Control and System Maintenance

FDA 21 CFR Part 11 -- Electronic Records and Electronic Signatures, Section 11.10(a--k)

ICH E6(R2) GCP, Section 5.5.3 -- Computerized Systems Validation and Change Documentation